ImmunoVaccine Inc. (TSE:IMV) Director Andrew J. Sheldon purchased 9,500 shares of the company’s stock in a transaction that occurred on Thursday, March 22nd. The stock was bought at an average cost of C$1.99 per share, for a total transaction of C$18,905.00.
Shares of ImmunoVaccine stock opened at C$2.00 on Friday. ImmunoVaccine Inc. has a one year low of C$1.00 and a one year high of C$2.55. The stock has a market cap of $255.47, a price-to-earnings ratio of -22.22 and a beta of 0.55.
COPYRIGHT VIOLATION NOTICE: This piece was posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3299104/immunovaccine-inc-imv-director-acquires-c18905-00-in-stock.html.
Immunovaccine Inc, a clinical stage biopharmaceutical company, develops cancer immunotherapies and infectious disease vaccines based on its DepoVax platform. The company's DepoVax platform is a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system.
Receive News & Ratings for ImmunoVaccine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoVaccine and related companies with MarketBeat.com's FREE daily email newsletter.